

The Patent Is Dead; Long Live The Royalties!

Pharma & Medtech Business Intelligence

05.13.2015

An upcoming Supreme Court ruling could extend product royalties beyond the life of a patent, and thus have a major impact on pharma and medtech deal structures and bottom lines. This article covers what companies need to do now to prepare.

[The Patent Is Dead; Long Live The Royalties! – Pharma & Medtech Business IntelligenceDownload](#)

Related People:

Erik Paul Belt

Basam E. Nabulsi